• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Cathie Wood-Led Ark Invest Scoops Up $5.16M Worth Of Palantir Shares Amid Raging AI Fervor

    7/1/24 10:19:40 PM ET
    $ADPT
    $BLDE
    $PLTR
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Transportation Services
    Consumer Discretionary
    Get the next $ADPT alert in real time by email

    On Monday, Cathie Wood-led Ark Invest made a notable investment in Palantir Technologies Inc (NYSE:PLTR), a move that comes as the AI sector gains momentum.

    The PLTR Trade

    Ark Invest, through its ARK Autonomous Technology & Robotics ETF (BATS:ARKQ), purchased 199,372 shares of Palantir, a significant addition to its portfolio. The value of this trade, based on the closing price of $25.88 on the same day, stands at approximately $5.16 million.

    Palantir has recently been praised as an ‘AI Halo’ play by momentum investors. The company was added to BofA Securities’ top 10 best U.S. ideas list for the third quarter, highlighting its growing popularity in the AI sector. Joe Terranova of Virtus Investment Partners explained that Palantir is a key player in the AI space, participating actively in the AI halo.

    Palantir co-founder Peter Thiel recently shared his insights on the AI landscape at the Aspen Ideas Festival, drawing parallels between the dot-com bubble and the current state of AI.

    Other Key Trades:

    • Ark Invest’s ARKG bought shares of Adaptive Biotechnologies Corp (NASDAQ:ADPT).
    • ARKK purchased shares of Recursion Pharmaceuticals Inc (NASDAQ:RXRX). ARKQ also added shares of Blade Air Mobility Inc (NASDAQ:BLDE) to its portfolio.
    • ARKF sold shares of Teladoc Health Inc (NYSE:TDOC).

    Read Next: Jim Cramer Says Trump’s Return To White House Could Be ‘Good For Your Portfolio:’ ‘Hate Him Or Like Him’

    This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal

    Get the next $ADPT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADPT
    $BLDE
    $PLTR
    $RXRX

    CompanyDatePrice TargetRatingAnalyst
    Teladoc Health Inc.
    $TDOC
    3/10/2026$11.00Hold → Buy
    Deutsche Bank
    Palantir Technologies Inc.
    $PLTR
    2/27/2026$150.00Buy
    Rosenblatt
    Palantir Technologies Inc.
    $PLTR
    2/27/2026$150.00Neutral → Buy
    UBS
    Teladoc Health Inc.
    $TDOC
    2/26/2026$7.00Neutral → Buy
    BofA Securities
    Palantir Technologies Inc.
    $PLTR
    2/18/2026$195.00Neutral → Outperform
    Mizuho
    Palantir Technologies Inc.
    $PLTR
    2/10/2026$180.00Neutral → Buy
    Daiwa Securities
    Palantir Technologies Inc.
    $PLTR
    2/3/2026$205.00Hold → Buy
    HSBC Securities
    Palantir Technologies Inc.
    $PLTR
    2/3/2026$190.00Market Perform → Outperform
    Northland Capital
    More analyst ratings

    $ADPT
    $BLDE
    $PLTR
    $RXRX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Paulus Kenneth H bought $69,400 worth of shares (10,000 units at $6.94) (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    11/17/25 4:05:05 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Planishek Heather A. bought $1,161,400 worth of shares (10,000 units at $116.14), increasing direct ownership by 21% to 58,006 units (SEC Form 4)

    4 - Palantir Technologies Inc. (0001321655) (Issuer)

    5/12/25 7:57:39 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    Director Mckinley Thomas bought $30,756 worth of shares (4,000 units at $7.69), increasing direct ownership by 11% to 39,077 units (SEC Form 4)

    4 - Teladoc Health, Inc. (0001477449) (Issuer)

    9/13/24 5:14:02 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $ADPT
    $BLDE
    $PLTR
    $RXRX
    SEC Filings

    View All

    SEC Form DEF 14A filed by Teladoc Health Inc.

    DEF 14A - Teladoc Health, Inc. (0001477449) (Filer)

    4/7/26 4:05:25 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    SEC Form DEFA14A filed by Teladoc Health Inc.

    DEFA14A - Teladoc Health, Inc. (0001477449) (Filer)

    4/7/26 4:05:47 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Teladoc Health Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Teladoc Health, Inc. (0001477449) (Filer)

    3/30/26 5:32:35 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    $ADPT
    $BLDE
    $PLTR
    $RXRX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    March 5, 2021 - Coronavirus (COVID-19) Update: FDA Authorizes Adaptive Biotechnologies T-Detect COVID Test

    For Immediate Release: March 05, 2021 Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the T-Detect COVID Test developed by Adaptive Biotechnologies. The T-Detect COVID Test is a next generation sequencing based (NGS) test to aid in identifying individuals with an adaptive T cell immune response to SARS-CoV-2, indicating recent or prior infection with SARS-CoV-2.  “Today’s authorization further und

    3/5/21 10:37:33 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $BLDE
    $PLTR
    $RXRX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Teladoc Health to Announce First Quarter 2026 Financial Results

    NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release first quarter 2026 results on Wednesday, April 29, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing (800) 715-9871 for U.S. participants and using the conference ID # 2214924. For international participants, please visit the following link for global dial-in numbers, using the same conference ID # 2214924: https://registrations.events/directory/international/itfs.html. A live audio webca

    4/15/26 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

    SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours a

    4/15/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palantir Announces Date of First Quarter 2026 Earnings Release and Webcast

    Palantir Technologies Inc. (NASDAQ:PLTR) announced today that results for its first quarter ended March 31, 2026 will be released on Monday, May 4, 2026, following the close of U.S. markets. Palantir will host a webcast to discuss its results at 5:00 PM ET. A live webcast and replay will be available at investors.palantir.com, and participants can pre-register here. In addition, shareholders can submit and vote on questions by visiting https://app.saytechnologies.com/palantir-2026-q1. About Palantir Technologies Inc. Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com. View source version on businesswire.com: https://w

    4/13/26 4:05:00 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    $ADPT
    $BLDE
    $PLTR
    $RXRX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Moore Alexander D.

    4 - Palantir Technologies Inc. (0001321655) (Issuer)

    4/17/26 8:06:25 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    SEC Form 4 filed by Rubinstein Julie

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    4/16/26 7:36:22 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by Rubinstein Julie

    4 - Adaptive Biotechnologies Corp (0001478320) (Issuer)

    4/13/26 7:44:10 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $BLDE
    $PLTR
    $RXRX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Blade Air Mobility Inc.

    SC 13G/A - Blade Air Mobility, Inc. (0001779128) (Subject)

    12/10/24 1:28:44 PM ET
    $BLDE
    Transportation Services
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by Palantir Technologies Inc.

    SC 13G/A - Palantir Technologies Inc. (0001321655) (Subject)

    11/14/24 5:47:09 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Adaptive Biotechnologies Corporation

    SC 13G - Adaptive Biotechnologies Corp (0001478320) (Subject)

    11/13/24 4:30:24 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $BLDE
    $PLTR
    $RXRX
    Leadership Updates

    Live Leadership Updates

    View All

    Teladoc Health Appoints Susan Salka, Experienced Healthcare Executive, to Its Board of Directors

    NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE:TDOC), the global leader in virtual care, today announced the appointment of Susan Salka to its board of directors, effective immediately. Ms. Salka is the former president and CEO of AMN Healthcare Services, a provider of healthcare workforce technology solutions and staffing services to healthcare facilities across the US. She joins following the retirements of Eric Evans and Thomas McKinley and the appointment of Michael Smith. She will serve on the board's audit and compensation committees. "Susan brings a powerful combination of healthcare leadership and governance experience to the Board," said Kenneth H. Paulus, non‑

    3/30/26 4:30:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Companies Unveiling Autonomous Defense System Amid Surge Toward $43 Billion Global Market

    Integrated AI system empowers forces to detect, decide, and deploy faster than traditional command structuresNEW YORK, March 30, 2026 /CNW/ -- Market News Updates News Commentary - Autonomous systems are transforming defense operations by enabling militaries to conduct missions with reduced human intervention, increased precision, and faster decision-making cycles. These systems include unmanned aerial vehicles (UAVs), ground robots, maritime platforms, and AI-enabled command systems that support intelligence, surveillance, reconnaissance (ISR), and combat roles. Their integration is largely driven by advancements in artificial intelligence, sensor fusion, and real-time data processing, allo

    3/30/26 8:45:00 AM ET
    $GE
    $KTOS
    $PDYN
    Consumer Electronics/Appliances
    Technology
    Military/Government/Technical
    Industrials

    Recursion Announces Vicki Goodman, M.D., as Incoming Chief Medical Officer

    Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ:RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion's Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with p

    3/25/26 7:59:00 AM ET
    $RXRX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADPT
    $BLDE
    $PLTR
    $RXRX
    Financials

    Live finance-specific insights

    View All

    Teladoc Health to Announce First Quarter 2026 Financial Results

    NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Teladoc Health Inc. (NYSE:TDOC), the global leader in virtual care, announced that it will release first quarter 2026 results on Wednesday, April 29, 2026, after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. ET on the same day. Conference Call Details The conference call can be accessed by dialing (800) 715-9871 for U.S. participants and using the conference ID # 2214924. For international participants, please visit the following link for global dial-in numbers, using the same conference ID # 2214924: https://registrations.events/directory/international/itfs.html. A live audio webca

    4/15/26 4:05:00 PM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026

    SEATTLE, April 15, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will report financial results for the first quarter 2026 after market close on Tuesday, May 5, 2026. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the "Investors" section of the company website at: www.adaptivebiotech.com. The webcast will be archived and available for replay within 24 hours a

    4/15/26 4:05:00 PM ET
    $ADPT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Palantir Announces Date of First Quarter 2026 Earnings Release and Webcast

    Palantir Technologies Inc. (NASDAQ:PLTR) announced today that results for its first quarter ended March 31, 2026 will be released on Monday, May 4, 2026, following the close of U.S. markets. Palantir will host a webcast to discuss its results at 5:00 PM ET. A live webcast and replay will be available at investors.palantir.com, and participants can pre-register here. In addition, shareholders can submit and vote on questions by visiting https://app.saytechnologies.com/palantir-2026-q1. About Palantir Technologies Inc. Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com. View source version on businesswire.com: https://w

    4/13/26 4:05:00 PM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    $ADPT
    $BLDE
    $PLTR
    $RXRX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Teladoc upgraded by Deutsche Bank with a new price target

    Deutsche Bank upgraded Teladoc from Hold to Buy and set a new price target of $11.00

    3/10/26 8:39:03 AM ET
    $TDOC
    Medical/Nursing Services
    Health Care

    Rosenblatt initiated coverage on Palantir Technologies with a new price target

    Rosenblatt initiated coverage of Palantir Technologies with a rating of Buy and set a new price target of $150.00

    2/27/26 8:31:30 AM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology

    Palantir Technologies upgraded by UBS with a new price target

    UBS upgraded Palantir Technologies from Neutral to Buy and set a new price target of $150.00

    2/27/26 8:22:27 AM ET
    $PLTR
    Computer Software: Prepackaged Software
    Technology